IntegenX awarded contract for rapid detection of engineered bacteria

IntegenX, Inc., has been awarded the first phase of a $2.8 million contract to develop an integrated sample-to-sequence system that would help in the rapid detection and identification of genetically engineered bacteria and viruses.

The contract was awarded by the Defense Threat Reduction Agency, which is a branch of the U.S. Department of Defense. Although the first phase of the contract is worth $2.8 million, the contract could be extended into a 22-month, $14.8 million contract, reports.

Dr. Stevan Jovanovich, president and CEO of IntegenX, said that the ISS system also can also be used to identify medically relevant bacteria and viruses and emerging pathogens.

Jovanavich said IntegenX will use its Universal Sample Preparation Module to purify DNA from pathogen targets in complex matrices.

“The ISS System will provide DoD and the country with a much-needed system to detect genetically engineered and emerging pathogens,” Jovanavich said, reports. “This will help protect our country, and others, against genetically engineered bioagents. There is no system to detect such threats today.”

Ezra van Gelder, the executive vice president of research and development for IntegenX, said he is excited about the contract.

“Our experience in next-generation sequencing library preparation and making a sample-to-answer system for forensic human identity testing has uniquely positioned IntegenX to accomplish the requirements that DTRA has requested,” van Gelder told “IntegenX technology integrates the processes to incorporate the complex steps into a complete and straightforward sample-to-sequence workflow.”

Organizations in this Story

U.S. Department of Defense

Want to get notified whenever we write about U.S. Department of Defense ?
Next time we write about U.S. Department of Defense, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.